论文部分内容阅读
目的探讨罗红霉素对支气管哮喘患者的治疗作用及其作用机理。方法 38例非急性发作期哮喘患者和 2 0例健康人 ,采用放射免疫法和分光光度法测定血清超氧化物歧化酶 (SOD)、过氧化氢酶 (CAT)活性及丙二醛 (MDA)含量 ;测定 1秒钟用力容积 (FEV1)及呼气峰值流速 (PEF)。结果哮喘患者SOD、CAT活性低于健康对照组 (P <0 .0 1,P <0 .0 5 ) ,MDA含量高于正常对照组 (P <0 .0 1) ;SOD、MDA含量与FEV1呈显著相关性 (分别r =0 .4 2 ,- 0 .38,P <0 .0 1) ;沙丁胺醇吸入治疗后比治疗前SOD、CAT、MDA含量无明显变化 (P >0 .0 5 ) ,沙丁胺醇吸入 +罗红霉素组治疗后较沙丁胺醇吸入组治疗后SOD、CAT活性升高 (P <0 .0 5 ) ,MDA含量下降 (P <0 .0 5 ) ,症状体征评分下降 (P <0 .0 5 ) ,FEV1及PEF值升高 (P <0 .0 5 )。结论氧化 /抗氧化失衡是哮喘发病的重要机理之一 ,罗红霉素能通过调节氧化 /抗氧化失衡而治疗哮喘。其抗炎活性与抑制氧化物的产生有关。
Objective To investigate the therapeutic effect and mechanism of roxithromycin on patients with bronchial asthma. Methods Serum levels of superoxide dismutase (SOD), catalase (CAT) and malondialdehyde (MDA) were measured by radioimmunoassay and spectrophotometry in 38 non-acute asthmatic patients and 20 healthy controls. Content; determination of 1 second forced volume (FEV1) and peak expiratory flow rate (PEF). Results The activities of SOD and CAT in asthmatic patients were lower than those in healthy controls (P <0.01, P <0.05), and the contents of MDA were higher than those in normal controls (P <0.01) (R = 0.42, -0.38, P <0.01). There were no significant changes in SOD, CAT and MDA levels after salbutamol inhalation therapy (P> 0.05) (P <0.05), the content of MDA decreased (P <0.05), and the symptom score decreased (P <0.05), while the effect of salbutamol inhalation and roxithromycin treatment was higher than that of salbutamol inhalation group <0.05), FEV1 and PEF increased (P <0.05). Conclusion Oxidation / antioxidant imbalance is one of the important mechanisms of asthma. Roxithromycin can treat asthma by regulating the imbalance of oxidation / antioxidation. Its anti-inflammatory activity and inhibition of oxide production.